Какова цена за Redx Pharma Plc (REDX)

Цена за Redx Pharma Plc (REDX) Это $0.20410523

Какова рыночная капитализация для Redx Pharma Plc (REDX)

Рыночная капитализация для Redx Pharma Plc (REDX) Это $793.94K

Redx Pharma Plc (REDX) Дивидендная доходность

Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.

Год	Дивидендная доходность	Изменить
Недостаточно данных для указанных дат.

Год

Дивидендная доходность

Изменить

Недостаточно данных для указанных дат.

Компания	Дивидендная доходность	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.65%	BE

Компания

Дивидендная доходность

Страна